%3Aformat(webp)&w=3840&q=75)
aXichem: Milestone reached, launch in sight
Research update Q2 2026
|2026-08-31
- Positive scientific opinion from EFSA
- Chr. Olesen fulfilled the call-off order in Brazil
- We increase our fair value to SEK 3.39 (3.07) per share
aXichem reported revenue of SEK 4 million and an operating result of SEK -4.3 million for the second quarter. Over the summer, the company also took an important step toward a European market launch of the feed additive aXiphen: EFSA has issued a positive scientific opinion confirming that the product is safe and can inhibit salmonella in animal feed. What remains is formal approval from the European Commission, which normally follows EFSA's recommendation. In parallel, redemption of the TO2A warrant is taking place from 7 to 18 September. We have updated our forecast following the Q2 report and raise our fair value to SEK 3.39 (3.07) per share.
Read our research update. The research update is available in Swedish
%3Aformat(webp)&w=3840&q=75)
Tobias Karlsson
Analyst
%3Aformat(webp)&w=3840&q=75)
Jacob Murat
Analyst